Show simple item record

dc.date.accessioned2021-01-07T06:37:24Z
dc.date.available2021-01-07T06:37:24Z
dc.date.issued2014
dc.identifier.urihttp://repository.kippra.or.ke/handle/123456789/2534
dc.description.abstractThis study examines the state of and factors that influence the availability of two maternal health medicines–oxytocin and misoprostol–in Kenya’s health facilities that offer basic emergency obstetric care (BEmOC). These medicines are used to prevent and treat post-partum haemorrhage, which (at 25%) is the leading cause of maternal mortality in Kenya.The study made use of the Kenya Public Expenditure Tracking and Service Delivery Indicators Survey (PETS+) data collected by KIPPRA in 2012 for the Ministry of Health. Using a survey logit model, the study found that the availability of oxytocin and misoprostol in BEmOC facilities is significantly determined by: the location of the facility, the type of health facility, the owner of facility (government or private not-for-profit organizations), availability of maternity waiting room in facilities, the type of procurement system used, the number of deliveries, delivery charges, amount of funds received by facilities for medical drugs, prompt procurement of out-of-stock medicines, and the number of health workers involved in the management of essential medicines and medical supplies.en
dc.language.isoenen
dc.publisherThe Kenya Institute for Public Policy Research and Analysis (KIPPRA)en
dc.relation.ispartofseriesDP/165/2014
dc.subjectMaternal Healthen
dc.subjectHealth Facilitiesen
dc.subjectMaternal Mortalityen
dc.subjectKenyaen
dc.titleDiscussion Paper No. 165 of 2014 on Predictors of Availability of Maternal Health Medicines in Kenya's Health Facilitiesen
dc.typeDiscussion Paperen
ppr.contributor.authorMuriithi, Grace Njeri


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record